BionicM Secures $4.5 Million in Series B Round to Expand Innovative Prosthetics

BionicM's Recent Funding Achievement

BionicM Inc., headquartered in Tokyo, has recently made headlines by securing 710 million JPY (approximately USD 4.5 million) in the first closing of its Series B financing round. This significant capital injection is instrumental as the company gears up for its U.S. expansion, fortifying its manufacturing capabilities and setting the stage for the commercial launch of its highly anticipated product, ASISTA, slated for 2027.

With the latest fundraising round, BionicM’s total accumulated funding now stands at an impressive 2.58 billion JPY, which encompasses both equity financing and government grants. This financing cycle included prominent investors such as B Dash Ventures Inc. and Mitsubishi UFJ Capital Co., Ltd., as well as contributions from individual angel investors and overseas backers.

Mission and Vision

BionicM is driven by the mission of 'Powering Mobility for All', and is focused on developing cutting-edge powered prosthetic limbs that integrate advanced robotics with human biomechanics. Their innovative product line began with the motorized powered prosthetic knee, known as the Bio Leg®, which has successfully achieved U.S. FDA Class II medical device approval and PDAC-verified reimbursement codes. As of 2026, its commitment to innovation was recognized through the Minister of Economy, Trade and Industry Award at the University-Launched Venture Awards.

Growth in the U.S. Prosthetics Market

The current landscape of prosthetics in the U.S. is undergoing a pivotal transformation driven by various factors, including an aging population and a rising incidence of diabetes. A marked shift towards the demand for prosthetics that offer active movement assistance rather than mere weight support is evident. There is an increasing need for solutions that help decrease physical strain and facilitate smoother daily functioning. Powered prosthetics, with capabilities for active movement generated by humanoid robotics, have gained attention in response to this emerging demand.

The year 2025 saw significant regulatory momentum for powered technologies, with newly introduced reimbursement codes focused on electromechanical control (such as motors and actuators), moving away from traditional fluid control systems. This regulatory shift has bolstered the market potential for motor-controlled prosthetics significantly.

Introducing ASISTA™

Forthcoming in 2027, ASISTA is set to revolutionize the microprocessor knee (MPK) category within the U.S. market. What sets ASISTA apart is its innovative